Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Boehringer Ingelheim - Focus on NSCLC treatment options

Treatments After Progression in the First-Line of Non-Mutated NSCLC Adenocarcinoma

Date

14 Sep 2020

Session

Boehringer Ingelheim - Focus on NSCLC treatment options

Presenters

Silvia Novello

Authors

S. Novello

Author affiliations

  • Oncology Dept., Università Degli Studi Di Torino - Orbassano, 10043 - Orbassano/IT
More

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings